-
CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark
Tuesday, May 28, 2024 - 10:57am | 751InnoCan Pharma Corp. (OTCQB:INNPF) (CSE:INNO) (FSE: IP4) an Israel-based cannabinoids-focused pharmaceutical company, announced its interim consolidated financial results Monday for the three months ended March 31, 2024. The company reported revenues of $6.8 million, marking a 334% increase...
-
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
Tuesday, April 23, 2024 - 10:24am | 513Innocan Pharma Corporation (CSE:INNO) (FSE: IP4) (OTCQB:INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration (FDA), for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. With the move, the...
-
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
Tuesday, April 2, 2024 - 4:28pm | 768Innocan Pharma Corporation (OTCQB:INNPF) (CSE:INNO) (FSE: IP4), a cannabinoids-focused pharmaceutical company based in Israel, announced Monday its financial results for the the year ended December 31, 2023. The company reported a nearly sixfold increase in its revenues, reaching US$13.7 million,...
-
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
Monday, August 28, 2023 - 10:13am | 373Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms, reported its financial results for Q2 2023. The company's CEO, Iris Bincovich, expressed excitement about the positive trajectory and strategic...
-
Innocan Pharma Q3 Revenue Grows 700% YoY, Here Is What You Need To Know
Tuesday, November 29, 2022 - 11:14am | 367Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) released its financial results for the three and nine months ended September 30, 2022, revealing Q3 revenue of $1.42 million, a 700% increase compared to $180,000 in the Q3 2021. Q3 2022 Financial Highlights Gross Profit - was $511,...
-
Ayurcann To Manufacture And Distribute Israel's Innocan Pharma's CBD Topicals In Canada
Wednesday, August 11, 2021 - 11:35am | 338Cannabis-focused extraction company Ayurcann Holdings Corp. (CSE: AYUR) has partnered with Israeli pharmaceutical tech company Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) to produce its CBD topical products. Under the deal, the Toronto-based company agreed to manufacture Innocan's...